Abstract: The present invention refers to a method for binding a polycarboxylic acid to a solid phase. Further, the invention refers to a solid phase having a polycarboxylic acid immobilized thereto and methods of using the solid phase, e.g. for purifying His-tagged recombinant polypeptides.
Type:
Grant
Filed:
August 6, 2008
Date of Patent:
July 7, 2015
Assignee:
Max-Planck-Gesellschaft zur Foerderung Der Wissenschaften e.V.
Abstract: This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide derivates have the general formula Sub1-X1 N X2 X3 P V Y I P X4 X5 R P P H P-Sub2 (SEQ ID NO:169) wherein X1 is a neutral or positively charged moiety, X2 is a polar or positively charged moiety, X3 is a positively charged moiety, X4 is a polar or positively charged moiety, X5 is a proline or a proline derivate, Sub1 being the free or modified N-terminus, and Sub2 being the free or modified C-terminus.
Abstract: An agent for suppressing elevation of blood GIP level, an agent for suppressing elevation of blood insulin level, an agent for lowering blood triglyceride level after meal ingestion and an agent for suppressing elevation of blood glucose level, these agents containing potassium polyglutamates as active ingredients.
Abstract: This invention provides derivatives of dodecapeptide ISSIKEKYPSHS (SEQ ID NO: 11) which interfere with binding of calbindin to inositol monophosphatase, and their use in treating mood disorders.
Type:
Grant
Filed:
May 14, 2009
Date of Patent:
June 16, 2015
Assignee:
Ben-Gurion University of the Negev Research and Development Authority
Abstract: Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.
Abstract: The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialization in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.
Type:
Grant
Filed:
May 21, 2006
Date of Patent:
May 19, 2015
Assignees:
Hadasit Medical Research Services and Development Ltd., Kyoto University
Abstract: Disclosed is a pharmaceutical composition of a hepatitis C viral protease inhibitor which is suitable for oral administration via a liquid- or semi-solid-filled capsule and methods of using this composition for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. The liquid- or semi-solid pharmaceutical composition of the present invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and hydrophilic surfactants.
Abstract: The invention provides a method of ameliorating a blood-brain barrier disorder, as well as a method of treating a disease accompanied by a blood-brain barrier disorder and a method of treating a cerebral ischemic disease, by administering a prothymosin ?, or a protein or polypeptide possessing the same function as the prothymosin ?. The invention also provides polypeptides useful in the context of the aforesaid methods.
Abstract: A bio-disc device including new valve control means and fluid movement system, a bio-driver apparatus in which a controller disc including a controller for the bio-disc is installed, and an assay method using the same, which are suitable for labs-on-a-chips for various diagnostic assays, nucleic acid hybridization assays, and immunoassays, are provided. The bio-driver apparatus is compatible with general optical discs, including audio CDs, CD-Rs, game CDs, DVDs, etc., and the assay method is compatible with general optical disc drivers, including CD-ROMs, DVD players, etc. Thus, the bio-driver apparatus and the assay method offer and economical and convenient alternative to existing products. In addition, the bio-driver apparatus can be readily and easily applied in connection with a computer for remote diagnosis via the Internet.
Abstract: Glucagon antagonists are provided which comprise amino acid substitutions and/or chemical modifications to glucagon sequence. In one embodiment, the glucagon antagonists comprise a native glucagon peptide that has been modified by the deletion of the first two to five amino acid residues from the N-terminus and (i) an amino acid substitution at position 9 (according to the numbering of native glucagon) or (ii) substitution of the Phe at position 6 (according to the numbering of native glucagon) with phenyl lactic acid (PLA). In another embodiment, the glucagon antagonists comprise the structure A-B-C as described herein, wherein A is PLA, an oxy derivative thereof, or a peptide of 2-6 amino acids in which two consecutive amino acids of the peptide are linked via an ester or ether bond.
Type:
Grant
Filed:
October 23, 2008
Date of Patent:
March 17, 2015
Assignee:
Indiana University Research and Technology Corporation
Abstract: The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.
Type:
Grant
Filed:
January 13, 2010
Date of Patent:
March 17, 2015
Assignees:
Schepens Eye Research Institute, Lubris LLC
Inventors:
Edward R. Truitt, III, Benjamin Sullivan, David Sullivan
Abstract: The present invention relates to methods for producing an oligonucleotide on a solid substrate surface and methods for using the same. Some aspects of the invention provide methods for selecting a single DNA molecule reproducibily with an atomic force microscope (AFM).
Type:
Grant
Filed:
November 16, 2009
Date of Patent:
March 10, 2015
Assignees:
Postech Foundation, Posco
Inventors:
Joon Won Park, Bong Jin Hong, Duk Hoe Kim
Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
Type:
Grant
Filed:
October 27, 2011
Date of Patent:
March 3, 2015
Assignees:
Baxter International Inc., Baxter Healthcare SA
Inventors:
Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
Abstract: Methods are disclosed relating to localizing nucleic acids to arrays such as silane-free arrays, and of sequencing the nucleic acids localized thereby.
Type:
Grant
Filed:
October 14, 2013
Date of Patent:
March 3, 2015
Assignee:
Illumina Cambridge Limited
Inventors:
Mark Edward Brennan Smith, Andrea Sabot, Isabelle Marie Julia Rasolonjatovo, Jean-Ernest Sohna Sohna, Adrian Martin Horgan, Harold Philip Swerdlow
Abstract: A method for screening a drug for cytochrome P450 (CYP) induction is provided and can include incubating the drug with a microsome-containing biological sample and then quantitating at least one cytochrome P450 isoform. The isoforms can be selected from 2B6, 3A4, 1A2, and 3A5 isoforms. In some embodiments, the method uses liquid chromatography tandem mass spectrometry (LC-MSMS). A quantitated value can be compared to a threshold value and the drug can be determined to exhibit an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. Isolated peptides are also provided.
Type:
Grant
Filed:
October 14, 2010
Date of Patent:
January 27, 2015
Assignee:
DH Technologies Development Pte. Ltd.
Inventors:
Brian L. Williamson, Subhasish Purkayastha
Abstract: A peptide of general formula (I): R1-(AA)nX1-X2-Arg-Arg-Gly-X3-X4-(AA)p-R2, and cosmetic and pharmaceutical compositions are disclosed that include at least one peptide of general formula (I), in a physiologically suitable medium. Also disclosed are methods for activating human transglutaminase to reinforce the skin barrier function and to stimulate epidermal regeneration and differentiation or for cosmetic treatment to treat signs of skin ageing, which include administering a composition containing the peptide of general formula (I) as an active ingredient.
Type:
Grant
Filed:
August 31, 2010
Date of Patent:
January 13, 2015
Assignee:
ISP Investments Inc.
Inventors:
Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
Abstract: A method of preparing a substrate with a composition comprising (i) an organoborane initiator and (ii) a radical curable component disposed thereon includes the step of depositing the composition onto the substrate wherein at least one of (i) the organoborane initiator and (ii) the radical curable component is deposited onto the substrate in the form of a gradient pattern. An article comprises the substrate and the gradient pattern formed on the substrate. The gradient pattern is formed from a developed composition comprising the reaction product of (i) the organoborane initiator and (ii) the radical curable component. By forming the gradient pattern on the substrate, combinatorial and high-throughput methods of generating and testing the developed composition are possible, which enable characterization of the developed composition for various physical and chemical properties.
Abstract: The present invention discloses compositions for applications that mimic fibronectin coated surfaces. Advantageously, such compositions provide an animal free (xeno-free, and human-component-free), synthetic, chemically defined surface that mimics at least one of the functionalities of fibronectin.
Abstract: The present invention relates to a process for the production of bivalirudin, a 20-mer peptide of formula H-(D)-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH (SEQ ID NO: 1).